PTGS2 and benign prostatic hyperplasia: Previous observations have indicated that two COX-2 selective inhibitors, rofecoxib and celecoxib, are effective as monotherapy or in combination with finasteride for the management of lower urinary tract symptoms in human BPH (33,34).